LncRNA SNHG4 Modulates EMT Signal and Antitumor Effects in Endometrial Cancer through Transcription Factor SP-1

Area of Science:

• Molecular Oncology
• Cancer Biology
• Genetics

Background:

• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in various cancers.
• The specific involvement and mechanisms of lncRNAs in endometrial cancer pathogenesis are not fully understood.
• Endometrial cancer is a significant gynecological malignancy with a need for improved therapeutic targets.

Purpose of the Study:

• To investigate the role of the lncRNA SNHG4 in endometrial cancer.
• To elucidate the molecular mechanisms underlying SNHG4's function in endometrial cancer.
• To evaluate SNHG4 as a potential biomarker for prognosis and therapy in endometrial cancer.

Main Methods:

• Quantitative real-time PCR to assess SNHG4 expression levels in endometrial cancer tissues.
• In vitro assays (proliferation, migration, invasion, cell cycle analysis) following SNHG4 knockdown.
• In vivo tumor xenograft models to evaluate the effect of SNHG4 on tumor growth.
• Investigation of the regulatory interaction between SNHG4 and the transcription factor SP-1.

Main Results:

• SNHG4 expression is significantly upregulated in endometrial cancer tissues and correlates with poor patient survival.
• Knockdown of SNHG4 suppressed endometrial cancer cell proliferation, migration, invasion, and tumor growth in vivo.
• SNHG4 influences the cell cycle and its activity is regulated by the transcription factor SP-1.

Conclusions:

• The lncRNA SNHG4 plays a critical role in promoting endometrial cancer progression.
• The SNHG4/SP-1 axis is a key pathway involved in endometrial cancer development.
• SNHG4 represents a promising therapeutic target and prognostic biomarker for endometrial cancer.